Comparing NKGen Biotech (NKGN) and Its Peers

NKGen Biotech (NYSE:NKGN) is one of 280 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare NKGen Biotech to similar businesses based on the strength of its earnings, dividends, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares NKGen Biotech and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-5,115.55%	-171.71%	-42.81%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NKGen Biotech and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	N/A
NKGen Biotech Competitors	1578	4710	12268	236	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 58.72%. Given NKGen Biotech’s competitors higher probable upside, analysts plainly believe NKGen Biotech has less favorable growth aspects than its competitors.

Risk and Volatility

NKGen Biotech has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s competitors have a beta of 1.08, suggesting that their average stock price is 8% more volatile than the S&P 500.

Earnings and Valuation

This table compares NKGen Biotech and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.08
NKGen Biotech Competitors	$556.01 million	-$34.22 million	-44.19

NKGen Biotech’s competitors have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 20.0% of NKGen Biotech shares are held by company insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.